% | $
Quotes you view appear here for quick access.


dynammo_humm 11 posts  |  Last Activity: May 21, 2015 8:12 AM Member since: Mar 29, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • dynammo_humm by dynammo_humm May 21, 2015 8:12 AM Flag

    I was playing solitaire on my I-Pad last night and a full screen ad for Empire and Allies came up. It had a good looking picture and a caption stating 'Over 2,00,000 Players".

    Nice way of targeting mobile gamers without spending too much money.

  • dynammo_humm by dynammo_humm Apr 30, 2015 12:36 PM Flag

    12:30 PM ET 04/30/2015

    MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Ocata Therapeutics, Inc. , a leader in the field of Regenerative Ophthalmology™, announced that a study has been published that includes top-line, positive results in Asian patients who were treated with Ocata’s proprietary RPE cells, manufactured using its DeltaCell™ Technology.

    These new data support previously reported positive long-term safety and signs of visual improvement, as presented in The Lancet of October 15th, 2014. The Korean study published online in Stem Cell Reports features twelve months of post-transplant follow-up data from four Asian patients; two with Stargardt’s macular degeneration (SMD) and two with dry age-related macular degeneration (AMD).

    “The results of this study conducted by CHA Biotech in Asian patients support the findings published in The Lancet in October 2014 and further underscores our leadership in regenerative ophthalmology,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “The safe treatment of a total of forty two patients across multiple studies with this novel therapeutic approach in geographically distinct patient populations is encouraging. We look forward to the planned initiation of our comprehensive Phase 2 safety study in dry AMD and a pivotal study in SMD, two disabling diseases where there is no cure available today.”

    In this study there was no evidence of adverse proliferation, tumorigenic behavior, ectopic tissue formation, or other serious safety issues related to the transplanted cells. Although designed as a safety study, visual acuity improved 9–19 letters in three patients and remained stable (+1 letter) in one patient. Vision was measured using the widely accepted standard for visual acuity testing, the Early Treatment Diabetic Retinopathy Study visual acuity exam.

    Robert Lanza, M.D., Chief Scientific Officer of Ocata Therapeutics ( OCAT ) and co-senior author of the paper, commented, “These results support the potential

  • Reply to

    Need the Bill Williams report on the CC

    by kdrobb Apr 23, 2015 5:36 PM
    dynammo_humm dynammo_humm Apr 23, 2015 6:00 PM Flag

    Thanks for the update. It is nice to see there is some intelligence left on these boards.

  • Reply to

    Must have said something good!

    by dynammo_humm Apr 23, 2015 5:02 PM
    dynammo_humm dynammo_humm Apr 23, 2015 5:39 PM Flag

    Any information is much appreciated. I was on my way home from work and could not listen.

  • dynammo_humm by dynammo_humm Apr 23, 2015 5:02 PM Flag

    Up 4% A.H.

  • dynammo_humm dynammo_humm Apr 22, 2015 2:53 PM Flag

    Just marking your post...

  • dynammo_humm by dynammo_humm Apr 22, 2015 8:49 AM Flag

    Entry into a Material Definitive Agreement, Change in Directors or Pr

    Item 1.01 Entry into a Material Definitive Agreement
    On April 21, 2015, Ampio Pharmaceuticals, Inc., a Delaware corporation ("Ampio" or the "Company"), entered into a Voting Agreement (the "Agreement") with Rosewind Corporation (OTCMKTS:RSWN), a Colorado corporation ("Rosewind") which is expected to be renamed Aytu BioScience, Inc. in the near future. Pursuant to the Agreement, Ampio agreed to vote all of the shares of common stock of Rosewind beneficially owned by Ampio at a special meeting of Rosewind's stockholders or by written consent in favor of the following proposals approved by the Board of Directors of Rosewind and authorizing Rosewind to
    (i) re-incorporate into the State of Delaware through a plan of conversion;
    (2) effectuate a reverse stock split of Rosewind's common stock, at a ratio of one new share for every approximately 12.174 shares currently outstanding;
    (3) change the name of Rosewind from "Rosewind Corporation" to "Aytu Bioscience, Inc."; and (4) approve a new stock option and incentive plan. The Agreement will remain in effect until Rosewind's stockholders approve the foregoing proposals. Ampio is the holder of approximately 81.5% of the common stock of Rosewind.

    The description of the Agreement set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text thereof, which is attached hereto as Exhibit 10.1.

    Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
    On April 16, 2015, Joshua R. Disbrow resigned as Chief Operating Officer of Ampio in connection with the Merger (as defined below) to assume the role of Chief Executive Officer of Rosewind, and Jarrett Disbrow resigned as President and Chief Executive Officer of Vyrix Pharmaceuticals, a Delaware corporation ("Vyrix"), and prior to the Merger a subsidiary of Ampio, to assume the role of Ch

  • I want to mark them! He knows everything!

  • dynammo_humm dynammo_humm Apr 21, 2015 8:33 AM Flag

    It will probably drift down a bit. The real story will be the companies explanation for the saline failure and guidance as to when they can re-submit data. From what I have read there is no controversy about the efficacy of the drug, just the unexplained results from the saline injected control group.

  • dynammo_humm dynammo_humm Apr 21, 2015 8:31 AM Flag

    Since there are no analysts following this stock I wonder who is going to downgrade them? You sound like someone fishing for cheap shares.

  • Good or bad Pincus says he will work for $1 per year. They have just shed Matrix's horrendous salary. That has to count for something.

6.16-0.08(-1.28%)9:50 AMEDT